The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Open accessAbstract
Pathological alterations to the locus coeruleus, the major source of noradrenaline in the brain, are histologically evident in early stages of neurodegenerative diseases. Novel MRI approaches now provide an opportunity to quantify structural features of the locus coeruleus in vivo during disease progression. In combination with neuropathological biomarkers, in vivo locus coeruleus imaging could help to understand the contribution of locus coeruleus neurodegeneration to clinical and pathological manifestations in Alzheimer’s disease, atypical neurodegenerative dementias and Parkinson’s disease. Moreover, as the functional sensitivity of the noradrenergic system is likely to change with disease progression, in vivo measures of locus coeruleus integrity could provide new pathophysiological insights into cognitive and behavioural symptoms. Locus coeruleus imaging also holds the promise to stratify patients into clinical trials according to noradrenergic dysfunction. In this article, we present a consensus on how non-invasive in vivo assessment of locus coeruleus integrity can be used for clinical research in neurodegenerative diseases. We outline the next steps for in vivo, post-mortem and clinical studies that can lay the groundwork to evaluate the potential of locus coeruleus imaging as a biomarker for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pietrzak, R. H., Gallezot, J., Ding, Y., Henry, S. E., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 130
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
The reward circuit: linking primate anatomy and human imaging
Haber, S. N., & Knutson, B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.129 · Cited by 3,718
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Cited by
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Locus coeruleus: a new look at the blue spot
Poe, G. R., Foote, S., Eschenko, O., Johansen, J. P., Bouret, S., Aston-Jones, G., Harley, C. W., Manahan-Vaughan, D., Weinshenker, D., Valentino, R., et al. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0360-9 · Cited by 720
Farmer, A. D., Strzelczyk, A., Finisguerra, A., Gourine, A. V., Gharabaghi, A., Hasan, A., Burger, A. M., Jaramillo, A. M., Mertens, A., Majid, A., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.568051 · Cited by 355
Self-citationMotor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Noradrenergic Responsiveness Supports Selective Attention across the Adult Lifespan
Dahl, M. J., Mather, M., Sander, M. C., & Werkle-Bergner, M. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0398-19.2020 · Cited by 72
Self-citationAntidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Costello, H., Roiser, J. P., & Howard, R. (2023) · Psychological Medicine · doi:10.1017/s003329172200397x · Cited by 60
“Degeneration of the LC occurs early in AD and Parkinson ’ s disease (PD) (Betts et al., 2019).”
Self-citationAssociations among locus coeruleus catecholamines, tau pathology, and memory in aging
Ciampa, C. J., Parent, J. H., Harrison, T. M., Fain, R. M., Betts, M. J., Maass, A., Winer, J. R., Baker, S. L., Janabi, M., Furman, D. J., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01269-6 · Cited by 54
Self-citationCapucciati, A., Zucca, F. A., Monzani, E., Zecca, L., Casella, L., & Hofer, T. (2021) · Antioxidants · doi:10.3390/antiox10060824 · Cited by 36
Self-citationState-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
Atomoxetine and citalopram alter brain network organization in Parkinson’s disease
Borchert, R. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, S. P., Vatansever, D., Vázquez Rodríguez, P., Ye, Z., Nombela, C., Hughes, L. E., et al. (2019) · Brain Communications · doi:10.1093/braincomms/fcz013 · Cited by 14
Self-citationEvidence and implications of abnormal predictive coding in dementia
Kocagoncu, E., Klimovich-Gray, A., Hughes, L. E., & Rowe, J. B. (2021) · Brain · doi:10.1093/brain/awab254 · Cited by 3
Self-citation
Metadata
- Authors
- Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., Loane, C., Keuken, M. C., Trujillo, P., Lüsebrink, F., Mattern, H., Liu, K. Y., Priovoulos, N., Fliessbach, K., Dahl, M. J., Maaß, A., Madelung, C. F., Meder, D., Ehrenberg, A. J., Speck, O., Weiskopf, N., Dolan, R., Inglis, B., Tosun, D., Morawski, M., Zucca, F. A., Siebner, H. R., Mather, M., Uludag, K., Heinsen, H., Poser, B. A., Howard, R., Zecca, L., Rowe, J. B., Grinberg, L. T., Jacobs, H. I. L., Düzel, E., & Hämmerer, D.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-20
- Volume
- 142
- Issue
- 9
- Pages
- 2558-2571
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2964104722
- Cited by
- 365
- References
- 136
- FWCI
- 28.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.